HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in BJP Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by HALLIDAY, J. Articles by McCREADIE, R. Search for Related Content PubMed PubMed Citation Articles by HALLIDAY, J. Articles by McCREADIE, R.

Nithsdale Schizophrenia Surveys 23: movement disorders

20-year review

Department of Clinical Research, Crichton Royal Hospital, Dumfries, UK

Correspondence: Dr Jennifer Halliday, Department of Clinical Research, Crichton Royal Hospital, Dumfries DG1 4TG, UK. Tel: 01387 244000; fax: 01387 257735; e-mail: mikejenq{at}tinyworld.co.uk

Declaration of interest None.

Background In the past 10 years the new atypical antipsychotic drugs have stimulated further interest in the pharmacological management of schizophrenia. The risk of movement disorders has been reported to be less with these new agents.

Aims To examine the current prevalence of movement disorders among all people with schizophrenia in a discrete geographical area, to compare the prevalence in patients receiving and not receiving atypical antipsychotic drugs; and to compare current prevalence with prevalence over the past 20 years.

Method In Nithsdale, south-west Scotland, in 1999/2000, we replicated previous studies by using the Abnormal Involuntary Movements Scale, Simpson—Angus scale and Barnes Akathisia Rating Scale to measure tardive dyskinesia, parkinsonism and akathisia, respectively. Mental state was assessed by the Positive and Negative Syndrome Scale.

Results In 136 patients the prevalence of probable tardive dyskinesia was 43%, of parkinsonism 35% and of akathisia 15%. Parkinsonism was present as often in those receiving atypicals as in those receiving standard oral antipsychotics. The prevalence of tardive dyskinesia has doubled over 20 years.

Conclusions Movement disorders remain significant problems for patients despite the introduction of atypical antipsychotic drugs.

Related articles in BJP:

Highlights of this issue

ELIZABETH WALSH
BJP 2002 181: 0. [Full Text]  

This article has been cited by other articles:

				R. A. Rosenheck, D. L. Leslie, and J. A. Doshi Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making Psychiatr Serv, May 1, 2008; 59(5): 515 - 520. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				K. L. Claxton, J. J. Chen, and D. M. Swope Drug-Induced Movement Disorders Journal of Pharmacy Practice, December 1, 2007; 20(6): 415 - 429. [Abstract] [PDF]

				R. A. Rosenheck Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics The British Journal of Psychiatry, September 1, 2007; 191(3): 238 - 245. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck, D. L. Leslie, J. Sindelar, E. A. Miller, H. Lin, T. S. Stroup, J. McEvoy, S. M. Davis, R. S.E. Keefe, M. Swartz, et al. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia Am J Psychiatry, December 1, 2006; 163(12): 2080 - 2089. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, October 1, 2006; 63(10): 1074 - 1076. [Full Text] [PDF]

				T. R. E. Barnes The Barnes Akathisia Rating Scale-Revisited J Psychopharmacol, December 1, 2003; 17(4): 365 - 370. [Abstract] [PDF]